ExpreS2ion Biotech: Signs Letter of Intent with WuXi Vaccines
15 april, 14:33
The company has today announced a Letter of Intent (LOI) with WuXi Vaccines, a subsidiary of WuXi Biologics – a leading vaccine Contract Development and Manufacturing Organization (CDMO) – regarding the ExpreS2™ technology platform. The evaluation will be conducted as part of a client project at WuXi and aims to determine whether the platform is suitable for the production of vaccines and other biologics. If the outcome is positive, it may lead to strategic collaboration discussions, potentially resulting in an agreement involving licensing, co-development, co-marketing, or other forms of strategic partnership.
No financial details were disclosed in today’s press release. However, CEO Bent Frandsen commented:
“We are exploring ways to expand the use of ExpreS2™, our recombinant protein production system, to a broader customer base in the vaccine industry. We value our association with WuXi Vaccines, a respected brand in this field, and hope our platform can benefit their clients, thereby supporting ExpreS2ion in promoting our technology.”
The ExpreS2™ platform is included in our valuation model for ExpreS2ion Biotech.
Read the full press release here: LOI with WuXi vaccines
Disclaimer: HC Andersen Capital receives payment from Expre2sion Biotech for a DigitalIR/Corporate Visibility agreement /Claus Thestrup, 15.04.2025, kl. 2:30 PM
Ämnen i artikeln
ExpreS2ion Biotech: Signs Letter of Intent with WuXi Vaccines
15 april, 14:33
The company has today announced a Letter of Intent (LOI) with WuXi Vaccines, a subsidiary of WuXi Biologics – a leading vaccine Contract Development and Manufacturing Organization (CDMO) – regarding the ExpreS2™ technology platform. The evaluation will be conducted as part of a client project at WuXi and aims to determine whether the platform is suitable for the production of vaccines and other biologics. If the outcome is positive, it may lead to strategic collaboration discussions, potentially resulting in an agreement involving licensing, co-development, co-marketing, or other forms of strategic partnership.
No financial details were disclosed in today’s press release. However, CEO Bent Frandsen commented:
“We are exploring ways to expand the use of ExpreS2™, our recombinant protein production system, to a broader customer base in the vaccine industry. We value our association with WuXi Vaccines, a respected brand in this field, and hope our platform can benefit their clients, thereby supporting ExpreS2ion in promoting our technology.”
The ExpreS2™ platform is included in our valuation model for ExpreS2ion Biotech.
Read the full press release here: LOI with WuXi vaccines
Disclaimer: HC Andersen Capital receives payment from Expre2sion Biotech for a DigitalIR/Corporate Visibility agreement /Claus Thestrup, 15.04.2025, kl. 2:30 PM
Ämnen i artikeln
Fonder
Bostadsmarknaden
Rapportsäsongen
-992x558.jpg&w=3840&q=75)
Aktieanalyser
Handelskriget
-992x558.jpg&w=3840&q=75)
-160x160.jpg&w=3840&q=75)
%2520(1).jpg&w=3840&q=75)
.png&w=3840&q=75)
Fonder
Bostadsmarknaden
Mest läst
Rapportsäsongen
Aktieanalyser
Handelskriget
Senaste nytt
privatekonomi
17 april, 15:56
Ekonomen: Så kan du göra med barnbidraget
aktier
17 april, 15:31
Så levererade rapportbolagen
Marknadsöversikt
OMX Stockholm 30
1 DAG %
−0,72%
Senast
2 355,58
1 mån
Loading market data...
Privatekonomi med Placeras expert
AFV
